Topic:

Clinical Trials

Latest Headlines

Latest Headlines

Robot eases kids' vaccination distress in study

Children who interacted with a robot while receiving their shots reported significantly less pain and distress than those in the control group, researchers write in the journal  Vaccine.

'Fraud' found at China site for key study of Pfizer and Bristol's Eliquis

Nearly 7 months since the FDA approved the blockbuster candidate Eliquis, media reports have shed light on data errors and a case of alleged fraud from clinical trial sites in China. The revelations in reports from Elsevier and Bloomberg could further harm the image of China as a hotspot for clinical development.

Expert exposes 'highly questionable' data from biotech Cardio3 after IPO

Last week Cardio3 BioSciences wrapped up a €23 million IPO, a deal that Forbes contributor Larry Husten argues was based on inconsistent data that he called "highly questionable."

Cytokinetics shares slide on dosing snafu in ALS drug study

Shares of Cytokinetics ($CYTK) plunged more than 10% this morning after the biotech awkwardly explained a dosing snafu in its sizable midstage study for an experimental treatment for ALS, or Lou Gehrig's disease.

UPDATED: Top Novartis blockbuster prospect whips Enbrel in psoriasis showdown

Novartis says that one of its top Phase III drug prospects beat out Enbrel in a head-to-head showdown on psoriasis. Investigators say that the anti-IL17A secukinumab (AIN457) nabbed all the primary and secondary endpoints in the study.

Lawsuits mount as India pushes trial reforms

For years, India's poor have been recruited into clinical trials with the promise of life-saving treatment, often without proper consent or education on side effects. Now, as the country works to tighten its regulations, more and more families are suing for retribution.

Parexel teams with Rutgers for clinical trials

Parexel has united with the Rutgers New Jersey Medical School in a long-term deal to host clinical trials on campus, giving the school a boost to its clinical research unit.

MannKind shoulders $160M in debt for PhIII inhaled-insulin gamble

MannKind is drawing close to raising the curtain on the long-awaited results of late-stage studies of its inhaled insulin Afrezza. And in anticipation of finally achieving success at the FDA, it's adding $160 million in new debt to prepare for a commercial launch.

Insmed shares routed on head-to-head antibiotic Phase III results

Bright and early this morning Insmed ($INSM) announced that its inhaled antibiotic Arikace hit its primary endpoint in a Phase III study and was awarded fast-track status at the FDA.

Resverlogix stock craters on failure of cardio drug trial

Resverlogix fell hard this afternoon on news that the company fell short in a midstage study of its lead HDL cholesterol-boosting drug. The Calgary-based biotech company said the Phase IIb study of RVX-208 failed to meet the goal of change in percent of atheroma volume in patients with a high risk of developing cardiovascular disease.